MX2010006109A - Moduladores de receptores de canabinoides. - Google Patents

Moduladores de receptores de canabinoides.

Info

Publication number
MX2010006109A
MX2010006109A MX2010006109A MX2010006109A MX2010006109A MX 2010006109 A MX2010006109 A MX 2010006109A MX 2010006109 A MX2010006109 A MX 2010006109A MX 2010006109 A MX2010006109 A MX 2010006109A MX 2010006109 A MX2010006109 A MX 2010006109A
Authority
MX
Mexico
Prior art keywords
hydrogen
formula
alkyl
radical
ring
Prior art date
Application number
MX2010006109A
Other languages
English (en)
Inventor
Anthony Murray
Thomas Hoegberg
Peter Aadal Nielsen
Jean-Michel Linget
Emelie Bjurling
Jean Marie Receveur
Pia Karina Noerregaard
Dorthe Almholt
Original Assignee
7Tm Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0724096A external-priority patent/GB0724096D0/en
Priority claimed from GB0813350A external-priority patent/GB0813350D0/en
Application filed by 7Tm Pharma As filed Critical 7Tm Pharma As
Publication of MX2010006109A publication Critical patent/MX2010006109A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) que son moduladores del receptor CB1 del canabinoide, útiles inter alia para el tratamiento de la obesidad: Fórmula (I). En donde: X es un enlace, o un radical divalente seleccionado de -C(R10) (R11)-*, -C(R10) (R11)-O-*, -C(R10) (R11)CH2-*, -C(R10) (R11)CH2-O-*, -CH2C(R10) (R11) *, - CH2C(R10) (R11)-O-*, y -CH2-O-C(R10) (R11)-*, en donde el enlace indicado por un asterisco está fijado al anillo de pirazol; Z es un radical de isóstero de carboxilo seleccionado del grupo especificado; R3 es hidrógeno, (C1-C3)alquilo o (C1-C3)fluoroalquilo; R4 es un radical de la fórmula -(Alq1)p-(Q1)r-(L)s-Q2 en donde p, r, s, L Q1 y Q2 son como se especificaron; o R3 y R4 tomados junto con el nitrógeno al cual los mismos están fijados forman un anillo de amino cíclico de 4 a 7 átomos del anillo que está substituido opcionalmente por un radical de la fórmula -(L)s-Q2 en donde s, L y Q2 san como se definieron anteriormente, o por un substituyente opcional seleccionado de hidroxi, metoxi, -NH2-, o mono o di-(C1-C3)alquilamino; R5, R6, R7 y R8 son seleccionados cada uno independientemente de hidrógeno -F, -C1, -Br, -CN, (C1-C3)alquilo, (C1-C3)fluoroalquilo, ciclopropilo, y -OR9; R10 es hidrógeno, (C1-C3)alquilo, hidróxilo o NH2, y R11 es hidrógeno o (C1-C3)alquilo; o R10 y R11 tomados junto con el átomo de carbono al cual los mismos están fijados, forman un anillo de (C3-C5) cicloalquilo.
MX2010006109A 2007-12-10 2008-12-08 Moduladores de receptores de canabinoides. MX2010006109A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0724096A GB0724096D0 (en) 2007-12-10 2007-12-10 Cannabinoid receptor modulators
GB0813350A GB0813350D0 (en) 2008-07-21 2008-07-21 Cannabinoid receptor modulators
PCT/GB2008/004051 WO2009074782A1 (en) 2007-12-10 2008-12-08 Cannabinoid receptor modulators

Publications (1)

Publication Number Publication Date
MX2010006109A true MX2010006109A (es) 2010-09-10

Family

ID=40344724

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006109A MX2010006109A (es) 2007-12-10 2008-12-08 Moduladores de receptores de canabinoides.

Country Status (14)

Country Link
US (1) US8173680B2 (es)
EP (1) EP2231615A1 (es)
JP (1) JP2011506410A (es)
KR (1) KR20100091255A (es)
CN (1) CN101896465A (es)
AU (1) AU2008334489A1 (es)
BR (1) BRPI0822061A2 (es)
CA (1) CA2708706A1 (es)
EA (1) EA018900B1 (es)
IL (1) IL205980A0 (es)
MX (1) MX2010006109A (es)
NZ (1) NZ585704A (es)
WO (1) WO2009074782A1 (es)
ZA (1) ZA201004828B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33200A (es) * 2010-01-26 2011-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
WO2013048989A2 (en) * 2011-09-30 2013-04-04 National Health Research Institutes Pyrazole compounds
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
IN2015DN03733A (es) 2012-11-13 2015-09-18 Us Health
US11155521B2 (en) * 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
CN104918922B (zh) 2012-12-20 2017-04-26 因森普深2公司 三唑酮化合物及其用途
CN105579440A (zh) 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用
US10329259B2 (en) 2014-05-09 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
JP2023509452A (ja) 2020-01-03 2023-03-08 バーグ エルエルシー がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
RU2007119315A (ru) * 2004-10-25 2008-11-27 Зольвай Фармасьютиклз Гмбх (De) Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
JP2008525404A (ja) * 2004-12-23 2008-07-17 アストラゼネカ アクチボラグ 治療剤
EP1928859A1 (en) * 2005-06-17 2008-06-11 Carex SA Pyrazole derivates as cannabinoid receptor modulators
JP5069894B2 (ja) * 2005-10-21 2012-11-07 田辺三菱製薬株式会社 ピラゾール化合物
AU2007226673A1 (en) * 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2007138050A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals B.V. Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
GB0622569D0 (en) * 2006-11-11 2006-12-20 7Tm Pharma As Cannabinoid receptor modulators
EP2121617B1 (en) * 2006-12-18 2014-01-22 7TM Pharma A/S Cb1 receptor modulators

Also Published As

Publication number Publication date
US8173680B2 (en) 2012-05-08
EA201000971A1 (ru) 2011-02-28
KR20100091255A (ko) 2010-08-18
CN101896465A (zh) 2010-11-24
BRPI0822061A2 (pt) 2015-06-23
ZA201004828B (en) 2011-03-30
IL205980A0 (en) 2010-11-30
JP2011506410A (ja) 2011-03-03
CA2708706A1 (en) 2009-06-18
US20100292273A1 (en) 2010-11-18
AU2008334489A1 (en) 2009-06-18
WO2009074782A1 (en) 2009-06-18
NZ585704A (en) 2012-08-31
EA018900B1 (ru) 2013-11-29
EP2231615A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
MX2010006109A (es) Moduladores de receptores de canabinoides.
MX2009006214A (es) Moduladores del receptor cb1.
NZ627878A (en) P2x4 receptor antagonist
MX2009013591A (es) Proceso para la preparacion de pirazoles.
EA201070323A1 (ru) Замещенное производное пиразола
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
MY164464A (en) Composition for metal electroplating comprising leveling agent
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
TW200720399A (en) Light-emitting element and iridium complex
MY158039A (en) Pest control composition
MX2010004893A (es) Compuesto heterociclico y composicion farmaceutica del mismo.
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
TW200643053A (en) Organoaluminum precursor compounds
MY160321A (en) Pesticidal composition and its use
MY159870A (en) Piperazine compound capable of inhibiting prostaglandin d synthase
IN2014DN02866A (es)
MY161134A (en) Piperazine compound having a pgds inhibitory effect
MX2010003576A (es) Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
PH12019500589A1 (en) Novel mesoionic insecticidal compound
WO2008108250A1 (ja) 軟質ポリウレタンフォーム製造用の触媒組成物
MY159842A (en) Plant disease control composition and its use
MX338146B (es) Composicion plaguicida y su uso.
WO2009005135A1 (ja) エポキシ樹脂用硬化剤及びエポキシ樹脂用硬化剤組成物
CA2666310A1 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
MX2017001104A (es) Agente de control de artropodos nocivos que contienen compuesto de amida.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal